This site is intended for U.S. healthcare professionals.
Menu
Close
Efficacy
Phase III Study Primary Endpoints
Success in ISGA: Clear or almost clear
Study Design
Phase III Study Secondary Endpoints
ISGA clear or almost clear
Time to ISGA success
Phase III Study: Other Endpoints
Pruritus
Quality of life assessments
Infant Study: Exploratory efficacy Endpoints
ISGA clear or almost clear
%BSA, EASI & POEM
Safety Data
Phase III Study Adverse Reactions*
Pivotal trial & 48-week extension study
Adverse Reactions
Open-Label Safety Extension Study*
Open-Label Safety Extension Study Rescue Therapy Endpoint
Study design
Infant Safety Study**
Adverse Reactions
Study design and Demographics
Savings & Support
Events
Materials
Videos
Copay Cards
Cost and Coverage
Success in ISGA, a stringent metric, is defined as Clear (0) or Almost Clear (1) AND at least a 2-grade improvement from baseline1 in patients 2 years and older
TRIAL 1
TRIAL 2
ISGA=Investigator’s Static Global Assessment
This study reflects information from the pivotal trial where patients enrolled were 2 years and older.
The Emollient-rich Vehicle control used in clinical studies is the same petrolatum-based, proprietary, nonmedicated ointment formulation in EUCRISA only without the active ingredient crisaborole. Ointments contain emollients which can help lock in moisture and soften the skin5.
Utilizing a vehicle arm is a standard way to test the effect of a topical product. Comparing EUCRISA to the vehicle provided evidence of the effect of the active ingredient, crisaborole, in pivotal trials.
Not an actual patient. For illustrative purposes only.
*Patients with clinical diagnosis of an ISGA of 4, 1, or 0 at baseline were excluded from enrollment.1,2
ISGA=Investigator's Static Global Assessment. The ISGA is primarily used in clinical trials and rarely used in clinical practice.1,3
Actual patient treated with EUCRISA in clinical trials, who achieved success in ISGA, the primary efficacy endpoint.*
All patients may not respond to treatment with EUCRISA. Individual results may vary.
Day 8
Day 15
BEFORE: Day 1 (ISGA 3)
Day 8 (ISGA 2)
Day 15 (ISGA 2)
Day 22
Day 22 (ISGA 2)
Day 29
AFTER: Day 29 (ISGA 1)
* Success in ISGA, a stringent metric, is defined as Clear (0) or Almost Clear (1) AND at least a 2-grade improvement from baseline at Day 29.1
This study reflects information from the pivotal trial where patients enrolled were 2 years and older.
† Prior AD treatment was utilized in 418 (41.0%) of EUCRISA patients and 230 (45.5%) of Emollient-Rich Vehicle patients. Prior AD treatment was not utilized in 598 (59.0%) of EUCRISA patients and 276 (54.5%) of Emollient-Rich Vehicle patients.
Prior AD therapy defined as any prior use of systemic or topical corticosteroids or topical calcineurin inhibitors for the treatment of AD within 90 days before starting the study.
Find out more about the proportion of patients aged 2 years and older who achieved ISGA clear or almost clear at day 29 from the Phase III trial's secondary endpoint
** This is an optional area where footnotes can live.
Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him
Not an actual patient
** This is an optional area where footnotes can live.
Learn more about 28-day, open-label, single-arm, safety study in 3 to <24 month old patients14
** This is an optional area where footnotes can live.
The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4
*Eligible patients pay as little as $10
Terms and Conditions apply
* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.
** This is an optional area where footnotes can live.
A savings and support program for your patients to help them with their access to EUCRISA
** This is an optional area where footnotes can live.
Register or sign in to check availability and request samples.
** This is an optional area where footnotes can live.
Contraindications
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
Adverse Reactions
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
Please see Full Prescribing Information and Patient Information
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?